Tuesday
May 13, 2025
4:05 PM ET
Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Tuesday
May 6, 2025
9:15 AM ET
Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13
Monday
May 5, 2025
8:00 AM ET
Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy
Tuesday
April 1, 2025
9:00 AM ET
Capricor Therapeutics to Present at the 2025 Piper Sandler Virtual Cardio Day
Wednesday
March 19, 2025
4:05 PM ET
Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Monday
March 17, 2025
9:25 AM ET
Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Tuesday
March 11, 2025
9:00 AM ET
Capricor Therapeutics to Present Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update on March 19
Friday
March 7, 2025
9:25 AM ET
Capricor Therapeutics to Present at Leerink’s Global Healthcare Conference 2025
Tuesday
March 4, 2025
7:00 AM ET
Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy
Monday
February 10, 2025
9:00 AM ET
Capricor Therapeutics to Participate in Upcoming Investor Conferences
Thursday
January 2, 2025
9:15 AM ET
Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Monday
December 2, 2024
4:15 PM ET
Capricor Therapeutics to Present at Upcoming Investor Conferences